Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. ALDX has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
ALDX stock price ended at $2.16 on Friday, after rising0%
The Aldeyra Therapeutics Inc stock price increased by 0% on the last trading day (16 May 2025), rising from 2.1 to 2.16. Throughout the last trading session, the stock experienced a fluctuation of 4.33% , ranging from a day low of $2.08 to a day high of 2.17. The price has declined in 5 of the last 10 days, resulting in a total change of -23.13% during this period. On the last day, trading volume increase by 290.85K shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 809.60K shares were traded, amounting to approximately 1.71M.
ALDX Technical Signals
ALDX(Aldeyra Therapeutics Inc Corp) has 1 buy signal and 3 sell signals now. The current trend is uptrend starting from 2025-05-14. The total price change during this trend is -0.46%. Recently, the price has decreased with an increase in volume, indicating a strong bearish signal. The average turnover of ALDX over the last 5 trading days is 2.11M. Overall, the technical indicator signals lean more toward a Bearish outlook in the mid-term.
ALDX Moving Average Analysis
Aldeyra Therapeutics Inc's overall moving average trend leans more bearish as of Saturday, May 17, 2025, with 3 negative signals and 1 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $2.8728933333333337, and $3.2243333333333335. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $1.7357733333333336, and $1.3843333333333336. A break-down below any of these levels will issue sell signals.
ALDX Short Selling Analysis
The short sale ratio of Aldeyra Therapeutics Inc(ALDX) as of 12 May 2025 is 26.59%, rising from last trading day. With increasing price from 2.18 to 2.21. The short sell activity indicate that short sellers may be anticipating a price reversion.
Technical Signal
Technical Signals Summary
Sell
3
Buy
1
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
1 Bullish Signals
1 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Moving Average
Price crosses above 5-day SMA
--
Bullish
3 Bearish Signals
3 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 < 0
-0.379
Bearish
Momentum (10 days)
MOM_10 < 0
-0.65
Bearish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 < 0
-0.378
Bearish
ALDX Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Aldeyra Therapeutics Inc(ALDX), our algorithm predicts ALDX's 1-month price at $2.17, with an -0.24%downwardshift. Using a similarity score up to 98.62%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Aldeyra Therapeutics Inc (ALDX.O) stock, as of Sunday, May 11, 2025 , forecasts a -0.24% change over the next month, based on its high correlation with TDUP.O stock patterns. The similarity between their price movements over the analyzed periods is 98.62%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
ALDX
No Data
TDUP
Down: -0.24%Similarity: 98.62%
Name
Similarity
Up/Down
TDUP.O
98.62%
-0.24%
SLDB.O
98.53%
-10.16%
PRTA.O
98.31%
+2.30%
HZO.N
98.25%
+14.98%
DNTH.O
98.18%
+73.91%
TIMB.N
98.08%
-5.45%
VVPR.O
98.07%
-8.56%
DOCU.O
97.99%
-5.92%
AQST.O
97.97%
+40.00%
JAKK.O
97.72%
+3.77%
ALDX Seasonality Analysis
Based on ALDX's historical stock price data across all years, the probability of a positive return in May is36.36%, suggesting it maynotbe an ideal month to invest in ALDX. In contrast,Julyoffers the highest probability of positive returns at60.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Aldeyra Therapeutics Inc (ALDX.O) stock in July has the highest probability of a positive return (60.00%), while June has the lowest probability (20.00%).
Performance Seasonality
The chart shows Aldeyra Therapeutics Inc. (ALDX)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Aldeyra Therapeutics Inc (ALDX.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. ALDX has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying Aldeyra Therapeutics Inc (ALDX.O) stock in a year?
The radar chart shows that buying Aldeyra Therapeutics Inc (ALDX.O) stock in July has the highest probability of a positive return (60.00%), while June has the lowest probability (20.00%).
How has Aldeyra Therapeutics Inc. (ALDX)'s stock price performed over the past three years?
ALDX's stock price fell by -49.57% in 2023,increased by 40.96% in 2024, and went down by 58.62% in 2025.
Is ALDX a buy based on overall technical signals summary?
ALDX has 1 buy signals and 3 sell signals now. Overall the technical rating for ALDX is Sell . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of ALDX.
What is the trend of Aldeyra Therapeutics Inc (ALDX)'s moving average?
Aldeyra Therapeutics Inc's overall moving average trend leans more bearish as of May 17 2025, with 3 negative signals and 1 positive signal.
What is price prediction for ALDX stock next month?
The price prediction chart for Aldeyra Therapeutics Inc (ALDX.O) stock, as of May 11 2025, forecasts a -0.24% change over the next month, based on its high correlation with TDUP stock patterns. The similarity between their price movements over the analyzed periods is 98.62%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for ALDX Stock?
### **Price Prediction for ALDX Stock in 2025**
Based on the analysis of technical indicators and recent news, here is the price prediction for ALDX stock in 2025:
1. **Price Prediction**: ALDX stock is expected to trade between **$1.50 and $3.50** in 2025.
2. **Reason**: The stock is currently under pressure due to the FDA setback for its lead drug, reproxalap, which caused a significant drop in price. However, the company plans to resubmit its NDA by mid-2025, and if successful, this could drive the stock higher. Until then, the stock is likely to remain volatile and range-bound.
What is price prediction 2030 for ALDX Stock?
ALDX stock could reach $5 by 2030, driven by potential recovery and pipeline success. The stock is currently undervalued with significant risks due to ongoing legal issues and failed drug trials.